EXTRAPOLATED FROM THE OMS DOCUMENT - JUNE 2023

Global research agenda for antimicrobial resistance in human health Policy brief

[…]
Topic 8. Antimicrobial medicines Investigate efficacious and safe antibiotic treatment regimens based on old and new agents and combinations for infections, especially for extended-spectrum beta-lactamase–producing and/or carbapenem-resistant Enterobacterales, with minimum selection and transmission risk for antimicrobial resistance, especially among children and other subpopulations experiencing vulnerability. Investigate efficacious and safe antibiotic treatment regimens for infections by drug-resistant typhoid and non-typhoidal salmonellae (including for pathogens resistant to cephalosporins and fluoroquinolones) across socioeconomic settings. Investigate efficacious and safe empirical antibiotic treatment (drug choice, drug combination, route, dose and duration) for gram-negative bacteria causing bloodstream infections or sepsis among neonates and young children, especially in settings with high antimicrobial resistance prevalence, limited diagnostic capacity, and antimicrobial medicine availability. Investigate antifungal regimens optimized for efficacy, cost, safety and duration for the treatment of infections caused by WHO fungal priority pathogens with critical importance for antimicrobial resistance (such as Candida auris, Aspergillus fumigatus and Cryptococcus neoformans) in settings with increasing or high prevalence of antifungal resistance. Investigate efficacious and safe regimens based on new or existing antimicrobial medicines for urogenital and extragenital sexually transmitted infections (such as resistant Neisseria gonorrhoeae and resistant Mycoplasma genitalium) in the context of increasing antimicrobial resistance levels, including in populations experiencing vulnerability (such as people living with HIV, pregnant women and adolescents).
[…]

DOWNLOAD DOCUMENT